Clinical Trial Update: Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL

View source ↗

Summary

Clinical trial update noting completion of a Use-Results Survey for ORENCIA (abatacept) 125 mg subcutaneous injection in rheumatoid arthritis patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ORENCIA (ABATACEPT)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Rheumatoid Arthritis | Status: COMPLETED